On Riemann method for solving a mixed problem

by A. N. Mironov
Published 2007-06-01

Riemann function formulation for two equations with leading partial derivatives

by A. N. Mironov
Published 2008-06-01

CLINICAL STUDIES OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF LIVE MONOVALENT INFLUENZA VACCINE (STRAIN А/17/CALIFORNIA/2009/38 — H1N1) IN CHILDREN

by D.S. Bushmenkov, A.N. Mironov, A.A. Romanova, A.A. Tsaan, I.V. Feldblyum
Published 2010-07-01

CLINICAL STUDIES OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF LIVE MONOVALENT INFLUENZA VACCINE (STRAIN А/17/CALIFORNIA/2009/38 — H1N1) IN CHILDREN

by D.S. Bushmenkov, A.N. Mironov, A.A. Romanova, A.A. Tsaan, I.V. Feldblyum
Published 2010-01-01

TOPOGRAPHIC AND ANATOMICAL FEATURES OF ANTEROLATERAL LIGAMENT OF THE KNEE

by E. N. Goncharov, O. A. Koval, G. O. Krasnov, A. N. Mironov, N. G. Goncharov
Published 2018-04-01

Investigation of rubella vaccine maked MICROGEN Federal State Company: study I trial

by A. N. Mironov, A. A. Tsaan, D. S. Bushmenkov, A. A. Romanova, Ye. S. Sidorenko, I. V. Feldblum
Published 2011-02-01

STUDY OF NEUROVIRULENT PROPERTIES OF VACCINE AGAINST CULTURAL LIVE RUBELLA

by A.N. Mironov, A.A. Tsaan, D.S. Bushmenkov, A.A. Romanova, V.A. Merkulov, N.N. Stepanov
Published 2010-07-01

STUDY OF NEUROVIRULENT PROPERTIES OF VACCINE AGAINST CULTURAL LIVE RUBELLA

by A.N. Mironov, A.A. Tsaan, D.S. Bushmenkov, A.A. Romanova, V.A. Merkulov, N.N. Stepanov
Published 2010-07-01

RISK ASSESSMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS

by R. N. Alyautdin, B. K. Romanov, A. N. Yavorsky, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov
Published 2018-02-01

Common technological processes used in manufacture of biomedical cell culture products

by M. V. Supotnitskiy, A. A. Elapov, V. A. Merkulov, I. V. Borisevich, V. I. Klimov, A. N. Mironov
Published 2018-02-01

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN

by A.N. Mironov, A.A. Romanova, R.Ya. Meshkova, I.V. Fel’dblyum, N.V. Kupina, D.S. Bushmenkov, A.A. Tsaan
Published 2010-07-01

Alipogene tiparvovec: a long journey of risk-benefit ratio assessment of gene therapy products

by R. N. Alyautdin, B. K. Romanov, A. P. Pereverzev, A. O. Chikalo, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov
Published 2018-02-01

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN

by A.N. Mironov, A.A. Romanova, R.Ya. Meshkova, I.V. Fel’dblyum, N.V. Kupina, D.S. Bushmenkov, A.A. Tsaan
Published 2010-01-01

Preparations of next generation monoclonal antibodies (issues and prospects)

by Zh. I. Avdeeva, A. A. Soldatov, N. A. Alpatova, N. V. Medunitsyn, V. P. Bondarev, A. N. Mironov, V. A. Merkulov, I. V. Sakaeva
Published 2018-02-01

The approaches to the assessment of biosimilarity of biotechnological preparations: quality issues

by A. N. Mironov, V. A. Merkulov, A. I. Lutseva, O. A. Vaganova, A. A. Bendryshev, T. A. Efremova, E. V. Kirichenko, S. V. Shvets, E. V. Ivanainen
Published 2018-02-01

Recombinant granulocyte colony stimulating factor biosimilars. Quality assessment

by Zh. I. Avdeeva, A. A. Soldatov, N. A. Alpatova, M. V. Kiselevsky, S. L. Lysikova, V. P. Bondarev, N. V. Medunitsyn, V. D. Mosyagin, V. A. Merkulov, A. N. Mironov
Published 2018-02-01

Vaccines with adjuvants. Preclinical studies

by Zh. I. Avdeeva, N. A. Alpatova, V. P. Bondarev, R. A. Volkova, N. I. Lonskaya, E. V. Lebedinskaya, N. V. Medunitsyn, A. N. Mironov, N. A. Ozeretskovsky, A. A. Soldatov, V. A. Shevtsov
Published 2018-02-01